Background Liver cirrhosis is considered a progressive disease that can eventually result in death. Vitamin D deficiency is prevalent in patients with cirrhosis. Few studies have been conducted on the effect of vitamin D supplementation in patients with cirrhosis. Objectives The aim of this study was to identify the effect of vitamin D supplementation on lipid profile, glycaemic indices and liver function tests in patients with cirrhosis. Methods Sixty patients with cirrhosis were involved in this double-blind, randomised controlled clinical trial. During the intervention, patients received one 50 000 IU pearl of vitamin D supplement or placebo per week for 12 weeks. Before and after supplementation, we assessed serum 25-hydroxy-vitamin-D3 (25(OH) D3), glycaemic indices (insulin, haemoglobin A1c, fasting blood glucose (FBG) and homeostatic model assessment for insulin resistance (HOMA-IR)), lipid profile and liver function tests. Results Baseline variables were not significantly different between groups. The present study indicated that over the 12 weeks, vitamin D supplementation significantly increased serum 25(OH) D3 (p<0.001), and also significantly decreased FBG (p=0.006), and HOMA-IR (p=0.001). Conclusions Vitamin D supplementation significantly improves FBG and HOMA-IR as well as serum 25(OH) D3 in patients with cirrhosis. Trial registration number The protocol of the study was registered at the Iranian Registry of Clinical Trials (IRCT) (IRCT20140502017522N2). Data are available upon reasonable request.

中文翻译：

---

补充维生素 D 对肝硬化患者血糖指数、血脂和肝功能检查的影响：双盲随机对照试验


背景 肝硬化被认为​​是一种进行性疾病，最终可能导致死亡。维生素 D 缺乏症在肝硬化患者中普遍存在。关于补充维生素 D 对肝硬化患者的影响的研究很少。目的 本研究的目的是确定补充维生素 D 对肝硬化患者血脂、血糖指数和肝功能测试的影响。方法 60 名肝硬化患者参与这项双盲、随机对照临床试验。干预期间，患者每周接受一颗 50 000 IU 珍珠维生素 D 补充剂或安慰剂，持续 12 周。补充前后，我们评估了血清 25-羟基维生素-D3 (25(OH) D3)、血糖指数（胰岛素、血红蛋白 A1c、空腹血糖 (FBG) 和胰岛素抵抗稳态模型评估 (HOMA-IR)） 、血脂和肝功能测试。结果 组间基线变量没有显着差异。本研究表明，在 12 周内，补充维生素 D 显着增加血清 25(OH) D3 (p<0.001)，并且还显着降低 FBG (p=0.006) 和 HOMA-IR (p=0.001)。结论补充维生素D可显着改善肝硬化患者的FBG、HOMA-IR以及血清25(OH)D3。试验注册号 该研究方案已在伊朗临床试验注册处（IRCT）注册（IRCT20140502017522N2）。数据可根据合理要求提供。